Year 2010-2014
17. Choughule A, Sharma R, Trivedi V, Thavamani A, Noronha V, Joshi A, Desai S, Chandrani P, Sundaram P, Utture S, Jambhekar N, Gupta S, Aich J*, Prabhash K*, Dutt A*. Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer. Br J Cancer. 2014 Nov 25;111(11) :2203-4.PubMed PMID: 25117816 *corresponding author
[READ] [SUMMARY]
18. Upadhyay P, Dwivedi R, Dutt A*. Application of NGS in Cancer Research. Current Science, 2014; 107 (5), 795 *corresponding author
[READ] [SUMMARY]
19. Barreto SG, Dutt A*, Adarsh Chaudhary. A Genetic Model for Gallbladder Carcinogenesis and its Dissemination. Annals of Oncology 2014 * corresponding author
[READ] [SUMMARY]
a) A commentary published on this work:HBSN(HEPATOBILIARY SURGERY AND NUTRITION)
[READ]
20. Chougule A, Prabhash K*, Noronha V, Joshi A, Thavamani A, Chandrani P, Upadhyay P, Utture S, Desai S, Jambhekar N, Dutt A*. Frequency of EGFR Mutations in 907 Lung Adenocarcioma Patients of Indian Ethnicity. PLoS One. 2013 Oct 4;8(10):e76164. doi: 10.1371/journal.pone.0076164. * corresponding authors
[READ] [SUMMARY]
21. Choughule A, Noronha V, Joshi A, Desai S, Jambhekar N, Utture S, Thavamanni A, Prabhash K,Dutt A. Epidermal growth factor receptor mutation subtypes and geographical distribution among Indian non-small cell lung cancer patients. Indian J Cancer. 2013 Apr-Jun;50(2):107-11. doi: 10.4103/0019-509X.117023.
[READ] [SUMMARY]
22. Noronha V, Prabhash K*, Thavamani A, Chougule A, Purandare N, Joshi A, Sharma R, Desai S, Jambekar N, Dutt A*, Mulherkar R. EGFR mutations in Indian lung cancer patients: clinical correlation and outcome to EGFR targeted therapy. PLoS One. 2013 Apr 19;8(4):e61561. doi: 10.1371/journal.pone.0061561. Print 2013. * corresponding authors
[READ] [SUMMARY]
23. Global Cancer Genomics Consortium.The Global Cancer Genomics Consortium’s Second Annual Symposium: Genomics Medicine in Cancer Research. Genes & Cancer, May/June 2013; vol. 4, 5-6: pp. 196-200., first published on April 17,2013
[READ]
24. Global Cancer Genomics Consortium. The Global Cancer Genomics Consortium: interfacing genomics and cancer medicine. Cancer Res. 2012 Aug 1;72(15):3720-4. Epub 2012 May 24
[READ]
25. Cho J, Pastorino S, Zeng Q, Xu X, Johnson W, Vandenberg S, Verhaak R, Cherniack AD, Watanabe H, DuttA,Kwon J, Chao YS, Onofrio RC, Chiang D, Yuza Y, Kesari S, Meyerson M.Glioblastoma-Derived Epidermal Growth Factor Receptor Carboxyl-Terminal Deletion Mutants Are Transforming and Are Sensitive to EGFR-Directed Therapies. Cancer Res. 2011 Dec 15;71(24):7587-96.
[READ]
26. Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W, Brace LE, Woods BA, Lin W, Zhang J, Deng X, Lim SM, Heynck SH, Peifer M, Simard JR, Lawrence MS, Onofrio RC, Salvesen HG, Seidel D, Zander T, Heuckmann JM, Soltermann A, Moch H, Koker M, Leenders F, Gabler F, Querings S, Ansen S, Brambilla E, Brambilla C, Lorimier P, Brustugun OT, Helland A, Petersen I, Clement JH, Groen H, Timens W, Sietsma H, Stoelben E, Wolf J, Beer DG, Tsao MS, Hanna M, Hatton C, Eck MJ, Janne PA, Johnson BE, Winckler W, Greulich H, Bass AJ, Cho J, Rauh D, Gray NS, Wong KK, Haura EB, Thomas RK, Meyerson M. Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer. Cancer Discovery. June 2011 1:78-89 This article featured as cover page article of the issue.
[READ]
27. Dutt A*, Ramos AH, Hammerman PS, Mermel C, Cho J, Sharifnia T, Chande A, Tanaka KE, Stransky N, Greulich H, Gray NS, Meyerson M*. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS One. 2011;6(6):e20351. *corresponding authors
[READ] [SUMMARY]
28. Zhou W, Hur W, McDermott U,Dutt A, Xian W, Ficarro SB, Zhang J, Sharma SV, Brugge J, Meyerson M, Settleman J, Gray NS. A structure-guided approach to creating covalent FGFR inhibitors. Chem Biol. 2010 Mar 26;17(3):285-95.
[READ]
Book Chapter
[READ]